CABA

IASO Biotherapeutics and Cabaletta Bio Announce Exclusive Worldwide License Agreement for Clinically Validated CD19 Binder

Retrieved on: 
Tuesday, October 11, 2022
SAN, U.S. Securities and Exchange Commission, B-cell lymphoma, Maxwell, NMPA, Disease, B-ALL, Risk, BCMA, IND, Multiple myeloma, NDA, Degenerative disease, Patient, Security (finance), Annual report, CABA, NMOSD, Mortality, ODD, CARTA, Nasdaq, CAR, Cancer, Private Securities Litigation Reform Act, MuSK protein, Form 10-K, Public health, NHL, CEO, Safety, Autoimmunity, CD19, Greater, Acute lymphoblastic leukemia, Lymphoid leukemia, ALL, Breakthrough therapy, Neuromyelitis optica spectrum disorder, Pharmaceutical industry, Vaccine, Cabaletta, COVID-19

IASO Bio has the right of first negotiation to develop and commercialize Cabaletta's products using the licensed sequence in the Greater China region.

Key Points: 
  • IASO Bio has the right of first negotiation to develop and commercialize Cabaletta's products using the licensed sequence in the Greater China region.
  • "Our collaboration with IASO Bio allows Cabaletta to utilize a CD19 binder in CABA-201, our newly designed, CD19-targeting CAR T product candidate.
  • The CD19 binder has been clinically evaluated with safety data that we believe support clinical development in patients with autoimmune diseases," said Steven Nichtberger, M.D., Chief Executive Officer and Co-founder of Cabaletta.
  • "We are very pleased to enter a collaboration with Cabaletta," said Wen (Maxwell) Wang, M.D., Ph.D., CEO of IASO Bio.

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Cabaletta Bio, Inc., of Class Action Lawsuit and Upcoming Deadline – CABA

Retrieved on: 
Thursday, April 28, 2022
Register, Securities Exchange Act of 1934, IPO, Lists of action films, Patient, CABA, GLOBE, Pemphigus, MPV, Pomerantz, Complaint, Registration statement, Court, District court, LLP, Person, Clinical trial, Securities Act of 1933, Company, Lists of schools in England, Haemophilia A, News, Cabaletta, Form, NASDAQ, SEC, Defendant, Prospectus, Ext, Security (finance), Pharmaceutical industry

To discuss this action, contact Robert S. Willoughby at [email protected] or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext.

Key Points: 
  • To discuss this action, contact Robert S. Willoughby at [email protected] or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext.
  • Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
  • Cabaletta, a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.

CABALETTA DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Cabaletta Bio, Inc. and Encourages Investors to Contact the Firm

Retrieved on: 
Thursday, April 28, 2022
Legal, Professional Services, IPO, CABA, District court, P.C, Court, Person, Company, Telephone, Lists of schools in England, Clinical trial, Cabaletta, NASDAQ, Jeanne Eagels, Security (finance)

Investors have until April 29, 2022 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

Key Points: 
  • Investors have until April 29, 2022 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
  • When the true details entered the market, the lawsuit claims that investors suffered damages.
  • is a nationally recognized law firm with offices in New York, California, and South Carolina.
  • The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country.

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Affirm, Cabaletta, Ericsson, and C3.ai and Encourages Investors to Contact the Firm

Retrieved on: 
Saturday, April 23, 2022
News, Adoption, IPO, Ericsson, International Consortium of Investigative Journalists, NASDAQ, American depositary receipt, Compliance, Cabaletta, GLOBE, CABA, Clinical trial, Lists of schools in England, Defendant, Technology, Shareholder, Company, ICIJ, American, Complaint, NYSE, Islam, Partnership, ADS, Baker Hughes, ISIS, Risk management, Renewable energy, Audit, Pharmaceutical industry, Tweet, P.C

Through its platform, the Company offers buy now, pay later or BNPL services to consumers.

Key Points: 
  • Through its platform, the Company offers buy now, pay later or BNPL services to consumers.
  • The Tweet was materially misleading, in that it omitted to disclose the full details of Affirms second quarter financial results.
  • Additionally, throughout the Class Period, Defendants made materially false and misleading statements regarding the Companys business, operations, and compliance policies.
  • For more information on the C3.ai class action go to: https://bespc.com/cases/AI
    About Bragar Eagel & Squire, P.C.

CABA 11-DAY DEADLINE ALERT: Hagens Berman, National Trial Attorneys, Encourages Cabaletta Bio (CABA) Investors with Significant Losses to Contact Firm’s Attorneys, Securities Fraud Class Action Pending

Retrieved on: 
Monday, April 18, 2022
NASDAQ, Fraud, News, Haemophilia A, Steve Berman (lawyer), Person, Pemphigus, CABA, GLOBE, Program, SEC, SAN, Tobacco, Pharmaceutical industry, Cabaletta

SAN FRANCISCO, April 18, 2022 (GLOBE NEWSWIRE) -- Hagens Berman urges Cabaletta Bio, Inc. (NASDAQ: CABA) investors who suffered significant losses to submit your losses now .

Key Points: 
  • SAN FRANCISCO, April 18, 2022 (GLOBE NEWSWIRE) -- Hagens Berman urges Cabaletta Bio, Inc. (NASDAQ: CABA) investors who suffered significant losses to submit your losses now .
  • A securities fraud class action has been filed and certain investors may have valuable claims.
  • Were focused on investors losses and proving defendants misrepresented the effectiveness of DSG3-CAART, said Reed Kathrein, the Hagens Berman partner leading the investigation.
  • If you invested in Cabaletta and have significant losses, or have knowledge that may assist the firms investigation, click here to discuss your legal rights with Hagens Berman .

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Affirm, Cabaletta, Ericsson, and C3.ai and Encourages Investors to Contact the Firm

Retrieved on: 
Monday, April 18, 2022
News, Adoption, IPO, Ericsson, International Consortium of Investigative Journalists, NASDAQ, American depositary receipt, Compliance, Cabaletta, GLOBE, CABA, Clinical trial, Lists of schools in England, Defendant, Technology, Shareholder, Company, ICIJ, American, Complaint, NYSE, Islam, Partnership, ADS, Baker Hughes, ISIS, Risk management, Renewable energy, Audit, Pharmaceutical industry, Tweet, P.C

Through its platform, the Company offers buy now, pay later or BNPL services to consumers.

Key Points: 
  • Through its platform, the Company offers buy now, pay later or BNPL services to consumers.
  • The Tweet was materially misleading, in that it omitted to disclose the full details of Affirms second quarter financial results.
  • Additionally, throughout the Class Period, Defendants made materially false and misleading statements regarding the Companys business, operations, and compliance policies.
  • For more information on the C3.ai class action go to: https://bespc.com/cases/AI
    About Bragar Eagel & Squire, P.C.

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Cerence, Affirm, Cabaletta, and Ericsson and Encourages Investors to Contact the Firm

Retrieved on: 
Tuesday, April 12, 2022
Company, CRNC, NASDAQ, Class Action, SEC Rule 10b-5, Ericsson, Compliance, ADS, ISIS, SEC, Securities Exchange Act of 1934, Cabaletta, Lists of schools in England, ICIJ, American, Car, Review, Islam, International Consortium of Investigative Journalists, CABA, American depositary receipt, COVID-19, GLOBE, Defendant, News, Clinical trial, IPO, Pharmaceutical industry, Risk management, Animal, Audit, Renewable energy, P.C, Tweet

Cerence is a Burlington, Massachusetts-based company that focuses on building artificial intelligence-powered virtual assistants primarily for the automotive market.

Key Points: 
  • Cerence is a Burlington, Massachusetts-based company that focuses on building artificial intelligence-powered virtual assistants primarily for the automotive market.
  • On that call, Cerence announced revenue guidance for fiscal year 2022 that was well below analysts expectations.
  • For more information on the Ericsson class action go to: https://bespc.com/cases/ERIC
    About Bragar Eagel & Squire, P.C.
  • The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country.

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Cabaletta Bio, Inc., of Class Action Lawsuit and Upcoming Deadline – CABA

Retrieved on: 
Thursday, April 7, 2022
Company, LLP, NASDAQ, Form, Complaint, Lists of action films, Pomerantz, Haemophilia A, Clinical trial, District court, Patient, Pemphigus, Register, SEC, Cabaletta, Court, Lists of schools in England, Prospectus, Securities Exchange Act of 1934, MPV, Person, CABA, Securities Act of 1933, GLOBE, Defendant, Ext, News, IPO, Registration statement, Security (finance), Pharmaceutical industry

To discuss this action, contact Robert S. Willoughby at [email protected] or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext.

Key Points: 
  • To discuss this action, contact Robert S. Willoughby at [email protected] or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext.
  • Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
  • Cabaletta, a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Cabaletta, Ericsson, C3.ai, and Rivian and Encourages Investors to Contact the Firm

Retrieved on: 
Thursday, April 7, 2022
Adoption, Offering, Company, NASDAQ, R1S, SUV, Complaint, Ericsson, NYSE, Compliance, ADS, Register, ISIS, Cabaletta, Lists of schools in England, ICIJ, American, Baker Hughes, Technology, Islam, International Consortium of Investigative Journalists, CABA, American depositary receipt, GLOBE, P.C, Phage r1t holin family, Defendant, News, Clinical trial, IPO, Registration statement, Partnership, Pharmaceutical industry, Audit, Real estate, Rivian

When the true details entered the market, the lawsuit claims that investors suffered damages.

Key Points: 
  • When the true details entered the market, the lawsuit claims that investors suffered damages.
  • On February 15, 2022, during intraday trading hours, Ericsson issued a press release disclosing media inquiries into its business dealings in Iraq.
  • Additionally, throughout the Class Period, Defendants made materially false and misleading statements regarding the Companys business, operations, and compliance policies.
  • For more information on the Rivian class action go to: https://bespc.com/cases/RIVN
    About Bragar Eagel & Squire, P.C.

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Affirm, Cabaletta, Ericsson, and C3.ai and Encourages Investors to Contact the Firm

Retrieved on: 
Saturday, April 2, 2022
Adoption, Company, NASDAQ, Shareholder, Complaint, Ericsson, NYSE, Compliance, ADS, ISIS, Cabaletta, Lists of schools in England, ICIJ, American, Baker Hughes, Technology, Islam, International Consortium of Investigative Journalists, CABA, American depositary receipt, GLOBE, Defendant, News, Clinical trial, IPO, Partnership, Risk management, Renewable energy, Audit, Pharmaceutical industry, P.C, Tweet

Through its platform, the Company offers buy now, pay later or BNPL services to consumers.

Key Points: 
  • Through its platform, the Company offers buy now, pay later or BNPL services to consumers.
  • The Tweet was materially misleading, in that it omitted to disclose the full details of Affirms second quarter financial results.
  • Additionally, throughout the Class Period, Defendants made materially false and misleading statements regarding the Companys business, operations, and compliance policies.
  • For more information on the C3.ai class action go to: https://bespc.com/cases/AI
    About Bragar Eagel & Squire, P.C.